What is Harvard Biosci's earnings per share (EPS)?

Harvard Biosci (HBIO) reported diluted earnings per share of $-1.28 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Harvard Biosci Financials

HBIO

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Harvard Biosci (HBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HBIO FY2025 2026-04-22

A non-cash balance-sheet reset swamped earnings, while the core business still produced positive free cash flow.

FY2025 looks like an accounting reset, not a pure cash-collapse year: goodwill fell by $46.8M while operating cash flow remained positive at $6.7M. That gap helps explain why the company reported a -$56.7M net loss even though free cash flow stayed positive, meaning the income statement and cash statement were telling very different stories.

Across FY2023-FY2025, gross margin stayed near 58% even as revenue contracted, so the underlying product economics did not collapse. The bigger issue is that a smaller sales base had to carry overhead and special charges, which is why margin stability at the gross level did not translate into operating stability.

Short-term liquidity improved, with the current ratio back above 2.0x in FY2025 and cash at $8.6M. That is a better near-term cushion than FY2024, but solvency is thinner than it looks because debt-to-equity reached 2.6x while equity fell to $13.7M.

Financial Health Signals

Financial Health Score 44/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Harvard Biosci's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Balance Sheet

Altman Z-Score Distress

-4.03

Harvard Biosci scores -4.03, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($28.1M) relative to total liabilities ($66.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

Harvard Biosci passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

-0.12x

For every $1 of reported earnings, Harvard Biosci generates $-0.12 in operating cash flow ($6.7M OCF vs -$56.7M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-37.4x

Harvard Biosci earns $-37.4 in operating income for every $1 of interest expense (-$48.6M vs $1.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$86.5M

YoY-8.1%

5Y CAGR-3.3%

10Y CAGR-2.2%

Harvard Biosci generated $86.5M in revenue in fiscal year 2025. This represents a decrease of 8.1% from the prior year.

EBITDA

-$42.8M

YoY-5652.5%

Harvard Biosci's EBITDA was -$42.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 5652.5% from the prior year.

Net Income

-$56.7M

YoY-357.1%

Harvard Biosci reported -$56.7M in net income in fiscal year 2025. This represents a decrease of 357.1% from the prior year.

EPS (Diluted)

$-1.28

Harvard Biosci earned $-1.28 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

$5.5M

YoY+554.4%

5Y CAGR-7.7%

Harvard Biosci generated $5.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 554.4% from the prior year.

Cash & Debt

$8.6M

YoY+109.7%

5Y CAGR+0.7%

10Y CAGR+2.5%

Harvard Biosci held $8.6M in cash against $35.9M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Harvard Biosci had 4M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

57.7%

YoY-0.5pp

5Y CAGR+0.8pp

10Y CAGR+12.8pp

Harvard Biosci's gross margin was 57.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.5 percentage points from the prior year.

Operating Margin

-56.1%

YoY-49.5pp

5Y CAGR-56.4pp

10Y CAGR-54.5pp

Harvard Biosci's operating margin was -56.1% in fiscal year 2025, reflecting core business profitability. This is down 49.5 percentage points from the prior year.

Net Margin

-65.5%

YoY-52.3pp

5Y CAGR-57.9pp

10Y CAGR-48.0pp

Harvard Biosci's net profit margin was -65.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 52.3 percentage points from the prior year.

Return on Equity

-412.8%

YoY-393.3pp

5Y CAGR-402.7pp

10Y CAGR-388.3pp

Harvard Biosci's ROE was -412.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 393.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$8.8M

YoY-15.2%

5Y CAGR+0.3%

10Y CAGR+3.2%

Harvard Biosci invested $8.8M in research and development in fiscal year 2025. This represents a decrease of 15.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.3M

YoY-52.4%

5Y CAGR+1.8%

Harvard Biosci invested $1.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 52.4% from the prior year.

HBIO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$86.5M-8.1%	$94.1M-16.1%	$112.3M-1.0%	$113.3M-4.7%	$118.9M+16.5%	$102.1M
Cost of Revenue	$36.6M-6.9%	$39.4M-14.7%	$46.2M-12.1%	$52.5M+2.5%	$51.3M+16.3%	$44.1M
Gross Profit	$49.9M-8.9%	$54.8M-17.1%	$66.1M+8.6%	$60.8M-10.1%	$67.7M+16.6%	$58.0M
R&D Expenses	$8.8M-15.2%	$10.4M-11.5%	$11.8M-4.6%	$12.3M+14.2%	$10.8M+24.3%	$8.7M
SG&A Expenses	$17.7M-17.5%	$21.5M-5.6%	$22.8M-7.1%	$24.5M+0.8%	$24.3M+3.4%	$23.5M
Operating Income	-$48.6M-682.2%	-$6.2M-427.9%	$1.9M+127.3%	-$6.9M-435.6%	$2.1M+834.8%	$221K
Interest Expense	$1.3M+62.5%	$800K	N/A	N/A	N/A	N/A
Income Tax	-$686K-192.7%	$740K-13.9%	$859K+154.9%	$337K+127.7%	$148K-71.4%	$518K
Net Income	-$56.7M-357.1%	-$12.4M-263.3%	-$3.4M+64.1%	-$9.5M-3204.2%	-$288K+96.3%	-$7.8M
EPS (Diluted)	$-1.28	$-0.28-250.0%	$-0.08+65.2%	$-0.23	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$20.8M-12.6%	$23.7M+15.3%	$20.6M+0.7%	$20.4M-6.1%	$21.8M-11.3%	$24.6M+11.8%	$22.0M-4.9%	$23.1M
Cost of Revenue	$8.5M-11.0%	$9.6M+11.6%	$8.6M-3.9%	$8.9M-7.0%	$9.6M-9.1%	$10.5M+14.6%	$9.2M-6.8%	$9.9M
Gross Profit	$12.2M-13.6%	$14.2M+17.9%	$12.0M+4.2%	$11.5M-5.3%	$12.2M-13.0%	$14.0M+9.8%	$12.8M-3.4%	$13.2M
R&D Expenses	$2.3M+6.6%	$2.2M+2.4%	$2.1M-2.6%	$2.2M-5.7%	$2.3M-0.3%	$2.3M-9.3%	$2.6M-2.2%	$2.6M
SG&A Expenses	$4.7M+14.2%	$4.1M-1.4%	$4.2M-2.0%	$4.3M-17.8%	$5.2M+8.0%	$4.8M-4.7%	$5.0M-11.3%	$5.7M
Operating Income	-$1.2M-168.7%	$1.7M+768.0%	$197K+124.1%	-$819K+98.4%	-$49.7M-451627.3%	$11K+100.6%	-$1.9M+9.4%	-$2.1M
Interest Expense	$1.3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$117K+132.8%	-$357K-468.0%	$97K+246.4%	$28K+106.2%	-$454K-179.4%	$572K+83.9%	$311K+188.1%	-$353K
Net Income	-$3.4M-20.3%	-$2.8M-131.3%	-$1.2M+46.1%	-$2.3M+95.5%	-$50.3M-279766.7%	$18K+100.4%	-$4.8M-64.1%	-$2.9M
EPS (Diluted)	$-0.77	N/A	$-0.03+40.0%	$-0.05+99.6%	$-11.42	N/A	$-0.11-57.1%	$-0.07

HBIO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$80.1M-36.8%	$126.6M-7.8%	$137.4M-5.5%	$145.4M-10.5%	$162.3M+3.9%	$156.3M
Current Assets	$48.2M+6.9%	$45.1M-8.0%	$49.0M-4.1%	$51.1M-17.0%	$61.6M+19.1%	$51.7M
Cash & Equivalents	$8.6M+109.7%	$4.1M-4.1%	$4.3M-5.0%	$4.5M-42.4%	$7.8M-6.0%	$8.3M
Inventory	$20.8M-10.5%	$23.2M-6.0%	$24.7M-6.5%	$26.4M-4.2%	$27.6M+23.9%	$22.3M
Accounts Receivable	$16.0M+7.9%	$14.9M-7.7%	$16.1M-3.6%	$16.7M-23.5%	$21.8M+22.9%	$17.8M
Goodwill	$9.6M-83.0%	$56.3M-1.3%	$57.1M+1.4%	$56.3M-2.5%	$57.7M-1.5%	$58.6M
Total Liabilities	$66.3M+4.8%	$63.3M-1.5%	$64.3M-12.1%	$73.1M-7.4%	$78.9M-0.8%	$79.6M
Current Liabilities	$22.0M-60.0%	$55.0M+107.1%	$26.5M+14.2%	$23.2M-8.2%	$25.3M+20.2%	$21.1M
Long-Term Debt	$35.9M	$0-100.0%	$30.7M-28.6%	$43.0M-4.6%	$45.1M-2.6%	$46.3M
Total Equity	$13.7M-78.3%	$63.3M-13.3%	$73.1M+1.2%	$72.2M-13.4%	$83.4M+8.8%	$76.7M
Retained Earnings	-$214.7M-35.9%	-$158.0M-8.5%	-$145.6M-2.4%	-$142.2M-7.2%	-$132.7M-0.2%	-$132.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$77.9M-2.7%	$80.1M+2.7%	$78.0M-2.6%	$80.1M+0.4%	$79.8M-37.0%	$126.6M-3.5%	$131.2M+1.8%	$128.9M
Current Assets	$47.5M-1.5%	$48.2M+10.1%	$43.8M-2.6%	$45.0M+0.1%	$44.9M-0.5%	$45.1M-3.6%	$46.8M+0.8%	$46.4M
Cash & Equivalents	$7.1M-17.6%	$8.6M+26.4%	$6.8M-8.4%	$7.4M+34.2%	$5.5M+35.0%	$4.1M-10.1%	$4.6M+12.9%	$4.0M
Inventory	$22.2M+6.7%	$20.8M-3.7%	$21.6M-2.9%	$22.3M-2.5%	$22.8M-1.8%	$23.2M-10.6%	$26.0M+3.4%	$25.1M
Accounts Receivable	$14.6M-9.2%	$16.0M+32.5%	$12.1M+1.4%	$11.9M-11.4%	$13.5M-9.3%	$14.9M+15.9%	$12.8M+2.8%	$12.5M
Goodwill	$9.4M-2.0%	$9.6M+0.4%	$9.5M-6.2%	$10.2M+13.3%	$9.0M-84.1%	$56.3M-1.9%	$57.4M+1.4%	$56.6M
Total Liabilities	$67.9M+2.3%	$66.3M+3.8%	$63.9M-0.7%	$64.4M-0.9%	$65.0M+2.6%	$63.3M-4.0%	$65.9M+6.9%	$61.7M
Current Liabilities	$23.9M+8.7%	$22.0M-59.6%	$54.4M-1.5%	$55.2M-0.7%	$55.6M+1.2%	$55.0M+141.6%	$22.8M+0.6%	$22.6M
Long-Term Debt	$36.2M+1.0%	$35.9M+5.6%	$34.0M-2.7%	$34.9M-4.1%	$36.4M	$0-100.0%	$34.3M+7.2%	$32.0M
Total Equity	$10.0M-26.9%	$13.7M-2.4%	$14.1M-10.6%	$15.7M+6.1%	$14.8M-76.6%	$63.3M-3.0%	$65.3M-2.9%	$67.2M
Retained Earnings	-$218.1M-1.6%	-$214.7M-1.3%	-$211.9M-0.6%	-$210.6M-1.1%	-$208.3M-31.9%	-$158.0M0.0%	-$158.0M-3.1%	-$153.2M

HBIO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$6.7M+367.3%	$1.4M-89.7%	$14.0M+1117.7%	$1.2M-8.7%	$1.3M-86.5%	$9.3M
Capital Expenditures	$1.3M-52.4%	$2.6M+47.9%	$1.8M+12.5%	$1.6M+33.1%	$1.2M+3.7%	$1.2M
Free Cash Flow	$5.5M+554.4%	-$1.2M-109.8%	$12.2M+2894.5%	-$438K-753.7%	$67K-99.2%	$8.2M
Investing Cash Flow	-$1.9M-38.6%	-$1.3M+25.3%	-$1.8M-13.1%	-$1.6M-18.2%	-$1.3M+4.1%	-$1.4M
Financing Cash Flow	-$1.3M-885.5%	-$131K+98.9%	-$12.1M-327.7%	-$2.8M-1025.8%	-$252K+96.8%	-$8.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$662K-589.6%	-$96K-108.9%	$1.1M-60.7%	$2.8M-7.7%	$3.0M+73.1%	$1.7M+304.9%	-$842K+0.5%	-$846K
Capital Expenditures	$426K-5.1%	$449K+116.9%	$207K+132.6%	$89K-82.7%	$513K+70.4%	$301K-65.8%	$880K+7.6%	$818K
Free Cash Flow	-$1.1M-99.6%	-$545K-162.1%	$877K-67.1%	$2.7M+7.8%	$2.5M+73.7%	$1.4M+182.7%	-$1.7M-3.5%	-$1.7M
Investing Cash Flow	-$620K-3.5%	-$599K-72.1%	-$348K-49.4%	-$233K+65.9%	-$683K-46.6%	-$466K+58.1%	-$1.1M-342.6%	$458K
Financing Cash Flow	-$9K-100.4%	$2.4M+291.6%	-$1.3M-1.6%	-$1.3M-4.5%	-$1.2M+11.3%	-$1.4M-164.5%	$2.1M+1088.7%	$177K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HBIO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	57.7%-0.5pp	58.2%-0.7pp	58.9%+5.2pp	53.7%-3.2pp	56.9%+0.0pp	56.9%
Operating Margin	-56.1%-49.5pp	-6.6%-8.3pp	1.7%+7.8pp	-6.1%-7.9pp	1.7%+1.5pp	0.2%
Net Margin	-65.5%-52.3pp	-13.2%-10.1pp	-3.0%+5.4pp	-8.4%-8.2pp	-0.2%+7.4pp	-7.6%
Return on Equity	-412.8%-393.3pp	-19.6%-14.9pp	-4.7%+8.5pp	-13.2%-12.8pp	-0.4%+9.8pp	-10.2%
Return on Assets	-70.8%-61.0pp	-9.8%-7.3pp	-2.5%+4.1pp	-6.6%-6.4pp	-0.2%+4.8pp	-5.0%
Current Ratio	2.20+1.4	0.82-1.0	1.85-0.4	2.20-0.2	2.43-0.0	2.46
Debt-to-Equity	2.61+2.6	0.00-0.4	0.42-0.2	0.60+0.1	0.54-0.1	0.60
FCF Margin	6.3%+7.6pp	-1.3%-12.2pp	10.9%+11.3pp	-0.4%-0.4pp	0.1%-8.0pp	8.0%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	59.0%-0.7pp	59.7%+1.3pp	58.4%+2.0pp	56.4%+0.4pp	56.0%-1.1pp	57.1%-1.0pp	58.1%+0.9pp	57.2%
Operating Margin	-5.7%-12.9pp	7.2%+6.2pp	1.0%+5.0pp	-4.0%+224.1pp	-228.1%-228.1pp	0.0%+8.6pp	-8.5%+0.4pp	-9.0%
Net Margin	-16.5%-4.5pp	-12.0%-6.0pp	-6.0%+5.2pp	-11.2%+220.0pp	-231.2%-231.3pp	0.1%+21.9pp	-21.9%-9.2pp	-12.7%
Return on Equity	-34.1%-13.4pp	-20.7%-12.0pp	-8.8%+5.8pp	-14.5%+324.8pp	-339.3%-339.4pp	0.0%+7.4pp	-7.3%-3.0pp	-4.3%
Return on Assets	-4.4%-0.8pp	-3.6%-2.0pp	-1.6%+1.3pp	-2.9%+60.2pp	-63.1%-63.1pp	0.0%+3.7pp	-3.7%-1.4pp	-2.3%
Current Ratio	1.99-0.2	2.20+1.4	0.810.0	0.810.0	0.81-0.0	0.82-1.2	2.060.0	2.05
Debt-to-Equity	3.60+1.0	2.61+0.2	2.41+0.2	2.22-0.2	2.45+2.5	0.00-0.5	0.52+0.0	0.48
FCF Margin	-5.2%-2.9pp	-2.3%-6.6pp	4.3%-8.8pp	13.0%+1.7pp	11.4%+5.6pp	5.8%+13.6pp	-7.8%-0.6pp	-7.2%

Similar Companies

Bionano Genomics Inc BNGO

$13.1M

Nexgel Inc NXGL

$4.7M

Retractable Tech RVP

$20.9M

Meihua International Medical Technologies Co., Ltd. MHUA

$425.4M

Precision Optics POCI

$54.2M

Frequently Asked Questions

What is Harvard Biosci's annual revenue?

Harvard Biosci (HBIO) reported $86.5M in total revenue for fiscal year 2025. This represents a -8.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Harvard Biosci's revenue growing?

Harvard Biosci (HBIO) revenue declined by 8.1% year-over-year, from $94.1M to $86.5M in fiscal year 2025.

Is Harvard Biosci profitable?

No, Harvard Biosci (HBIO) reported a net income of -$56.7M in fiscal year 2025, with a net profit margin of -65.5%.

What is Harvard Biosci's EBITDA?

Harvard Biosci (HBIO) had EBITDA of -$42.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Harvard Biosci have?

As of fiscal year 2025, Harvard Biosci (HBIO) had $8.6M in cash and equivalents against $35.9M in long-term debt.

What is Harvard Biosci's gross margin?

Harvard Biosci (HBIO) had a gross margin of 57.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Harvard Biosci's operating margin?

Harvard Biosci (HBIO) had an operating margin of -56.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Harvard Biosci's net profit margin?

Harvard Biosci (HBIO) had a net profit margin of -65.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Harvard Biosci's return on equity (ROE)?

Harvard Biosci (HBIO) has a return on equity of -412.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Harvard Biosci's free cash flow?

Harvard Biosci (HBIO) generated $5.5M in free cash flow during fiscal year 2025. This represents a 554.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Harvard Biosci's operating cash flow?

Harvard Biosci (HBIO) generated $6.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Harvard Biosci's total assets?

Harvard Biosci (HBIO) had $80.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Harvard Biosci's capital expenditures?

Harvard Biosci (HBIO) invested $1.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Harvard Biosci spend on research and development?

Harvard Biosci (HBIO) invested $8.8M in research and development during fiscal year 2025.

How many shares does Harvard Biosci have outstanding?

Harvard Biosci (HBIO) had 4M shares outstanding as of fiscal year 2025.

What is Harvard Biosci's current ratio?

Harvard Biosci (HBIO) had a current ratio of 2.20 as of fiscal year 2025, which is generally considered healthy.

What is Harvard Biosci's debt-to-equity ratio?

Harvard Biosci (HBIO) had a debt-to-equity ratio of 2.61 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Harvard Biosci's return on assets (ROA)?

Harvard Biosci (HBIO) had a return on assets of -70.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Harvard Biosci's Altman Z-Score?

Harvard Biosci (HBIO) has an Altman Z-Score of -4.03, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Harvard Biosci's Piotroski F-Score?

Harvard Biosci (HBIO) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Harvard Biosci's earnings high quality?

Harvard Biosci (HBIO) has an earnings quality ratio of -0.12x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Harvard Biosci cover its interest payments?

Harvard Biosci (HBIO) has an interest coverage ratio of -37.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Harvard Biosci?

Harvard Biosci (HBIO) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.